The American Journal of Medicine
Volume 121, Issue 1 , Pages 10-12 , January 2008

Chylomicronemia and the Chylomicronemia Syndrome: A Practical Approach to Management

  • David Alexander Leaf, MD, MPH

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to David Alexander Leaf, MD, MPH, Division of General Internal Medicine, 111G, Greater Los Angeles VA Healthcare System, Wilshire and Sawtelle Blvds, Los Angeles, CA 90073.

References 

  1. Parker F, Bagdade JD, Odland JF, Bierman EL. Evidenced for the chylomicron origin of lipids accumulating in diabetic eruptive xanthoma: a correlative lipid biochemical, histochemical and electron microscopic study. J Clin Invest. 1970;49:2172–2187
  2. Brunzell JD, Bierman EL. Chylomicronemia syndrome. Med Clin North Am. 1982;66:455–463
  3. Mostaza JM, Vega GL, Snell P, Grundy SM. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue. J Intern Med. 1998;243:265–274
  4. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults. JAMA. 2003;289:76–80
  5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356–359
  6. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2000;286:1195–2000
  7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  8. Grundy SM, Mok HY, Zech L, et al. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest. 1979;63:1274–1283
  9. Zavaroni I, Dall’Aglio E, Alpi O, et al. Evidence for an independent relationship between insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis. 1985;55:259–267
  10. Leaf DA, Illingworth DR, Connor WE. Lymphadenopathy associated with severe hypertriglyceridemia. JAMA. 1990;264:727–728
  11. Leaf DA, Parker DL, Schaad D. Changes in V02max, physical activity, and body fat with chronic exercise: effects on plasma lipids. Med Sci Sports Exerc. 1997;29:1552
  12. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group (Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin). N Engl J Med. 2002;346:393–403
  13. Stalenhoef AF, deGraaf J, Wittekoek ME, et al. The effect of concentrated fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity, and oxidizability in patients with hypertriglyceridemia. Atherosclerosis. 2000;153:129–138
  14. Chapman MJ. Fribrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis. 2003;171:1–13
  15. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S–1654S
  16. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy. 2007;27:715–728
  17. Venkata AR, Gandhi M, Braden R, et al. Effect of combination lipid-modifying therapy on the triglyceride lowering effect of fish oil. Am J Med Sci. 2007;333:168–172
  18. McKenny J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164:697–705
  19. Eriksson A, Attuau S, Bonnier M, et al. Short-term effect of metformin on type 2 diabetics. Diabetes Obes Metab. 2007;9:483–489
  20. Betteridge DJ. Effects of pioglitazone on lipid metabolism. Diabetes Obes Metab. 2007;9:640–647
  21. Connor WE. The dietary treatment of hypertriglyceridemia. Med Clin North Am. 1982;66:485

PII: S0002-9343(07)00987-4

doi: 10.1016/j.amjmed.2007.10.004

The American Journal of Medicine
Volume 121, Issue 1 , Pages 10-12 , January 2008

Article Tools

* Image Usage & Resolution